Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 30

1.

Primary care physician experiences with integrated pharmacogenomic testing in a community health system.

Lemke AA, Hutten Selkirk CG, Glaser NS, Sereika AW, Wake DT, Hulick PJ, Dunnenberger HM.

Per Med. 2017 Sep;14(5):389-400. doi: 10.2217/pme-2017-0036. Epub 2017 Aug 2.

PMID:
29754567
2.

Patient perspectives following pharmacogenomics results disclosure in an integrated health system.

Lemke AA, Hulick PJ, Wake DT, Wang C, Sereika AW, Yu KD, Glaser NS, Dunnenberger HM.

Pharmacogenomics. 2018 Mar;19(4):321-331. doi: 10.2217/pgs-2017-0191. Epub 2018 Feb 22.

PMID:
29469671
3.

Toward Genetics-Driven Early Intervention in Dilated Cardiomyopathy: Design and Implementation of the DCM Precision Medicine Study.

Kinnamon DD, Morales A, Bowen DJ, Burke W, Hershberger RE; DCM Consortium*.

Circ Cardiovasc Genet. 2017 Dec;10(6). pii: e001826. doi: 10.1161/CIRCGENETICS.117.001826.

4.

Using simulation and optimization approach to improve outcome through warfarin precision treatment.

Chi CL, He L, Ravvaz K, Weissert J, Tonellato PJ.

Pac Symp Biocomput. 2018;23:412-423.

5.

Indigenous Genetics and Rare Diseases: Harmony, Diversity and Equity.

Baynam G, Molster C, Bauskis A, Kowal E, Savarirayan R, Kelaher M, Easteal S, Massey L, Garvey G, Goldblatt J, Pachter N, Weeramanthri TS, Dawkins HJS.

Adv Exp Med Biol. 2017;1031:511-520. doi: 10.1007/978-3-319-67144-4_27. Review.

PMID:
29214589
6.

Improved Diagnosis and Care for Rare Diseases through Implementation of Precision Public Health Framework.

Baynam G, Bowman F, Lister K, Walker CE, Pachter N, Goldblatt J, Boycott KM, Gahl WA, Kosaki K, Adachi T, Ishii K, Mahede T, McKenzie F, Townshend S, Slee J, Kiraly-Borri C, Vasudevan A, Hawkins A, Broley S, Schofield L, Verhoef H, Groza T, Zankl A, Robinson PN, Haendel M, Brudno M, Mattick JS, Dinger ME, Roscioli T, Cowley MJ, Olry A, Hanauer M, Alkuraya FS, Taruscio D, Posada de la Paz M, Lochmüller H, Bushby K, Thompson R, Hedley V, Lasko P, Mina K, Beilby J, Tifft C, Davis M, Laing NG, Julkowska D, Le Cam Y, Terry SF, Kaufmann P, Eerola I, Norstedt I, Rath A, Suematsu M, Groft SC, Austin CP, Draghia-Akli R, Weeramanthri TS, Molster C, Dawkins HJS.

Adv Exp Med Biol. 2017;1031:55-94. doi: 10.1007/978-3-319-67144-4_4. Review.

PMID:
29214566
7.

Advancing Global Precision Medicine: An Overview of Genomic Testing and Counseling Services in Malaysia.

Balasopoulou A, Mooy FM, Baker DJ, Mitropoulou C, Skoufas E, Bulgiba A, Katsila T, Patrinos GP.

OMICS. 2017 Dec;21(12):733-740. doi: 10.1089/omi.2017.0136. Epub 2017 Nov 27. Review.

PMID:
29173101
8.

Institutional profile: translational pharmacogenomics at the Icahn School of Medicine at Mount Sinai.

Scott SA, Owusu Obeng A, Botton MR, Yang Y, Scott ER, Ellis SB, Wallsten R, Kaszemacher T, Zhou X, Chen R, Nicoletti P, Naik H, Kenny EE, Vega A, Waite E, Diaz GA, Dudley J, Halperin JL, Edelmann L, Kasarskis A, Hulot JS, Peter I, Bottinger EP, Hirschhorn K, Sklar P, Cho JH, Desnick RJ, Schadt EE.

Pharmacogenomics. 2017 Oct;18(15):1381-1386. doi: 10.2217/pgs-2017-0137. Epub 2017 Oct 6. Review.

9.

Implementation and utilization of the molecular tumor board to guide precision medicine.

Harada S, Arend R, Dai Q, Levesque JA, Winokur TS, Guo R, Heslin MJ, Nabell L, Nabors LB, Limdi NA, Roth KA, Partridge EE, Siegal GP, Yang ES.

Oncotarget. 2017 Jun 14;8(34):57845-57854. doi: 10.18632/oncotarget.18471. eCollection 2017 Aug 22. Review.

10.

Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi: 10.1002/cpt.602. Erratum in: Clin Pharmacol Ther. 2017 Jul;102(1):152.

PMID:
28027596
11.

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

Lynch J, DuVall SL, Berse B, Whatley A, St Pierre C, Oloruntoba O, Hunt CM.

Mil Med. 2016 Oct;181(10):1375-1381.

PMID:
27753578
12.

Challenges of development and implementation of point of care pharmacogenetic testing.

Haga SB.

Expert Rev Mol Diagn. 2016 Sep;16(9):949-60. doi: 10.1080/14737159.2016.1211934. Epub 2016 Jul 22. Review.

PMID:
27402403
13.

Comparing cytochrome P450 pharmacogenetic information available on United States drug labels and European Union Summaries of Product Characteristics.

Reis-Pardal J, Rodrigues A, Rodrigues E, Fernandez-Llimos F.

Pharmacogenomics J. 2017 Dec;17(6):488-493. doi: 10.1038/tpj.2016.40. Epub 2016 May 31.

PMID:
27241061
14.

Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation.

Loganadan NK, Huri HZ, Vethakkan SR, Hussein Z.

Pharmacogenomics J. 2016 Jun;16(3):209-19. doi: 10.1038/tpj.2015.95. Epub 2016 Jan 26. Review.

PMID:
26810132
15.

Rapid whole genome sequencing and precision neonatology.

Petrikin JE, Willig LK, Smith LD, Kingsmore SF.

Semin Perinatol. 2015 Dec;39(8):623-31. doi: 10.1053/j.semperi.2015.09.009. Epub 2015 Oct 29. Review.

16.

Association studies of genomic variants with treatment response to risperidone, clozapine, quetiapine and chlorpromazine in the Chinese Han population.

Xu Q, Wu X, Li M, Huang H, Minica C, Yi Z, Wang G, Shen L, Xing Q, Shi Y, He L, Qin S.

Pharmacogenomics J. 2016 Aug;16(4):357-65. doi: 10.1038/tpj.2015.61. Epub 2015 Aug 18.

PMID:
26282453
17.

Poor cell block adequacy rate for molecular testing improved with the addition of Diff-Quik-stained smears: Need for better cell block processing.

Harada S, Agosto-Arroyo E, Levesque JA, Alston E, Janowski KM, Coshatt GM, Eltoum IA.

Cancer Cytopathol. 2015 Aug;123(8):480-7. doi: 10.1002/cncy.21561. Epub 2015 May 8.

18.

KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.

Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, Troncone G.

J Clin Pathol. 2015 Apr;68(4):265-9. doi: 10.1136/jclinpath-2014-202761. Epub 2015 Jan 21.

PMID:
25609577
19.

An epidemiological perspective of personalized medicine: the Estonian experience.

Milani L, Leitsalu L, Metspalu A.

J Intern Med. 2015 Feb;277(2):188-200. doi: 10.1111/joim.12320. Review.

20.

Implementation and utilization of genetic testing in personalized medicine.

Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA.

Pharmgenomics Pers Med. 2014 Aug 13;7:227-40. doi: 10.2147/PGPM.S48887. eCollection 2014. Review.

Supplemental Content

Loading ...
Support Center